Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Applications of artificial intelligence in non-small cell lung cancer: from precision diagnosis to personalized prognosis and therapy.

PMID: 41437380 · 2025

JournalJournal of translational medicine
Year2025
PMID41437380

Abstract

Non-small cell lung cancer (NSCLC) carries a major global burden. The rapid growth of multimodal medical data challenges conventional methods to deliver stable, transferable and interpretable decisions across heterogeneous longitudinal high dimensional inputs. This review summarizes advances in artificial intelligence (AI) for NSCLC from 2023 to 2025 and outlines a translation-focused framework that links algorithmic progress to clinical utility. We survey thoracic imaging, digital pathology and

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.

↑